Rotigotine skin patch for the treatment of fluctuating Parkinson's disease - How does it compare with pramipexole? Commentary

Nature Clinical Practice Neurology

Volumn 3, Issue 12, 2007, Pages 656-657

  Pahwa, Rajesh ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; PLACEBO; PRAMIPEXOLE; ROPINIROLE; ROTIGOTINE;

ADD ON THERAPY; APPLICATION SITE ERYTHEMA; APPLICATION SITE PRURITUS; APPLICATION SITE REACTION; CLINICAL TRIAL; DIZZINESS; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSKINESIA; EVIDENCE BASED MEDICINE; HALLUCINATION; HUMAN; LONG TERM CARE; MAINTENANCE DRUG DOSE; MOTOR DYSFUNCTION; NAUSEA; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT COMPLIANCE; PRIORITY JOURNAL; SHORT SURVEY; SKIN MANIFESTATION; SOMNOLENCE; TRANSDERMAL PATCH; UNSPECIFIED SIDE EFFECT;

EID: 36949002785     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0632     Document Type: Short Survey

References (3)

1. Pahwa R et al. (2006) Practice parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66: 983-995
2. Watts RL et al. (2007) Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 68 272-276
3. LeWitt PA et al. (2007) Advanced Parkinson disease treated with rotigotine transdermal system: PREFER Study. Neurology 68: 1262-1267